Innovative CRISPR Editing to Create Off-the-Shelf Immune Cell Therapies

Rachel Haurwitz, PhD, is a co-founder of Caribou Biosciences and has been its President and Chief Executive Officer and a director since the company’s inception in 2011. She is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized her with the annual Next Generation Award. She serves on the board of directors of the Biotechnology Organization (BIO). Dr Haurwitz earned an AB in Biological Sciences from Harvard College and a PhD in Molecular and Cell Biology from the University of California, Berkeley.